Mabapi le C-CAR031

C-CAR031 ke phekolo ea autologous, e nang le GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) e shebaneng le eona ka ho khetheha, e ntseng e ithutoa bakeng sa kalafo ea HCC.

Tswelopele ya dipatlisiso ya C-CAR031 ho kankere ya sebete (HCC) e hlahisitswe ka molomo sebokeng sa selemo le selemo sa American Society of Clinical Oncology (ASCO) se neng se tshwaretswe Chicago ka 2024.

Mekhoa: Teko ea pele ea ho eketsa tekanyo e bulehileng ho motho e sebelisa titration e potlakileng hammoho le moralo oa i3+3. Li-pts tsa HCC tse tsoetseng pele tsa GPC3+ tse hlōlehileng kalafo ea ≥ 1 line systemic li fumane pheko e le 'ngoe ea iv ea C-CAR031 post standard lymphodepletion. Lintlha tsa mantlha ke polokeho le mamello, tse ling li kenyelletsa pharmacokinetics le katleho ea pele. Liketsahalo tse mpe (AEs) li ile tsa hlahlojoa ke CTCAE 5.0, 'me cytokine release syndrome (CRS) / immune effector cell-associated neurotoxicity syndrome (ICANS) li ile tsa hlahlojoa ho latela litekanyetso tsa ASTCT 2019. Karabelo ea sepheo e ile ea hlahlojoa ke mofuputsi ho latela RECIST 1.1.

Liphetho: Ho tloha ka la 5 Pherekhong, 2024, kakaretso ea lintlha tse 24 e ile ea fuoa infusion ea C-CAR031 maemong a 4 a tekanyo (DLs). Lintlha tsohle li ne li e-na le BCLC stage C HCC, 83.3% (20/24) e ne e e-na le metastasis ea extrahepatic. Palo e mahareng ea mela ea pele ea phekolo e ne e le 3.5 (sebaka sa 1-6), lintlha tse 23 (95.8%) li ile tsa fumana ICI (immune checkpoint inhibitors) le TKIs (tyrosine kinase inhibitors). Lintlha tsohle li ile tsa hlahlojoa bakeng sa polokeho. Ha ho na chefo e fokotsang tekanyo 'me ICANS e ile ea bonoa. CRS e ile ea bonoa maemong a 22 (91.7%) ka CRS ea 1 (4.2%) feela (G) 3. Li-AE tse tloaelehileng haholo tsa ≥G3 e ne e le lymphocytopenia (100%), neutropenia (70.8%), thrombocytopenia (37.5%) le ho phahama ha transaminase (16.7%). Karolo e le 'ngoe (4.2%) e ne e e-na le myelosuppression ea G4 le ntlha e le 'ngoe (4.2%) e ne e e-na le pneumonitis ea G3 interstitial ho DL4 e bakoang ke G3 CRS. Li-AE tsohle li ne li ka khutlisoa morao. Lintlha tse 22 li ile tsa hlahlojoa bakeng sa katleho. Ho fokotseha ha hlahala ho bonoe ho lintlha tse 90.9%, eseng feela ho liso tsa kahare ho sebete empa hape le ho tse ling tse nang le phokotso e mahareng ea 44.0% (sebaka, 3.4%-94.4%). Sekhahla sa taolo ea lefu e ne e le 90.9% 'me sekhahla sa karabelo ea sepheo (ORR) e ne e le 50.0% bakeng sa lintlha tsa li-DL tsohle. Ho DL4, ORR e ne e le 57.1%.

Liqeto: Phuputso e bontšitse boemo ba polokeho bo laolehang le ho khothaletsa ts'ebetso ea C-CAR031 khahlanong le hlahala ho bakuli ba HCC ba tsoetseng pele ba phekoloang haholo.

Hona jwale, ho ntse ho na le diteko tse ngata tsa bongaka tsa mahlale a matjha a ho lwantsha kankere Chaena a batlang bakudi. Dipuisano mabapi le meriana le mahlale a matjha, o ka ikopanya le Lefapha la Matjhaba la Sepetlele sa Oncology sa Beijing Region South.

Nomoro ea mohala: 4008803716

Email：myimmnet@163.com

Litšupiso

1.https://www.prnewswire.com/news-releases/abelzeta-announces-clinical-data-showing-preliminary-anti-tumor-activity-for-c-car031-an-armored-autologous-gpc3-car-t-in-patients-with-advanced-hepatocellular-carcinoma-at-asco-annual-meeting-2024-302162941.html

2.https://www.abelzeta.com/abelzeta-announces-abstract-for-c-car031-accepted-for-presentation-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting/

3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019

4.ASCO-2024-IR-Presentation.pdf (astrazeneca.com)